The Global Health Body Sounds Alert Over Severe Scarcity of Obesity Injections
Fewer than one in 10 people that would benefit from GLP-1 drugs including Wegovy are able to get them, warns the global health agency as it issues its first advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for broader and more equitable availability to this class of drugs.
Based on estimates, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The latest guidelines affirms that excess weight is a lifelong illness that can be addressed with comprehensive and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key obstacles to broad access to the treatments that can help people shift considerable body mass, notes the agency.
Weight-Loss Drug Scarcity
Even in the present most optimistic case, the production of these medications might only reach approximately 100 million people – fewer than 10% of those who need them, per the WHO.
The recommendation encourages nations and manufacturers to increase availability, via approaches such as patent sharing.
The intellectual property rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs imitate a biological compound to reduce digestion speed, curb appetite and increase feelings of fullness so individuals consume fewer calories.
People usually start to lose weight after several weeks of beginning the weekly injections.
Studies points to people may regain a significant portion after a year of discontinuing the drug, as their usual food cravings return.
Being above a healthy weight raises your risk for contracting diseases, including type 2 diabetes, heart disease, stroke, and certain cancers.
Obesity impacts individuals in all nations and was responsible for millions of fatalities worldwide in 2024, according to the WHO.
